A new HPLC method adjusted to our laboratory conditions was developed for the evaluation of assay and purity of clopidogrel in film-coated tablets.”
“Objective: To investigate whether a short interdelivery interval from cesarean section (CS) to a subsequent delivery is associated with adverse G418 concentration obstetric outcomes, and specifically uterine rupture.
Study design: A retrospective study was conducted, comparing all patients who delivered following CS during the years 1988-2010. Time interval was defined as the time from the day of CS to the day of the subsequent delivery. Women with multiple gestations or more than one previous CS were excluded from the study.
Results: Three-thousand
one-hundred and seventy-six deliveries were included in the study. Of these, 176 patients had an interval <12 month, 728 had an interval of 13-18 months, 635 had an interval of 19-24 months and 1637 had an interval of more than 24 AZD3965 months. The rate of uterine rupture did not differ between the groups. Patients with short interval of less than 12 month had higher rates of preterm deliveries (11.9% versus 4.9-6.6% in the other groups; p < 0.001). The rate of post partum perinatal death was comparable between the groups.
Conclusion: Short time interval is not a risk factor for major maternal and neonatal complications
such as uterine rupture and post-partum Selleckchem Compound C death. However, in our population,
it is a risk factor for preterm delivery.”
“Objective: To investigate the efficacy, toxicity, and drug discontinuation in patients with psoriatic arthritis treated with anti-tumor necrosis factor agents.
Methods: Sixty-five patients with active disease were included in this open-label study. They had tender or swollen joint count Psoriatic Arthritis Severity Index (PAST) score >= 10, and erythrocyte sedimentation rate >= 28 mm Hg/1st hour and/or C-reactive protein >= 10 mg/L. All were refractory to at least 2 disease-modifying antirheumatic drugs. Thirty were treated with influximab, 25 with etanercept, and 10 with adalimumab. Infliximab (5 mg/kg body weight) was given intravenously at weeks 0, 2, 6, and every 8 weeks thereafter; etanercept was given subcutaneously (25 mg twice a week), while adalimumab was given subcutaneously (40 mg every other week) for a period of 5 years. Data concerning anti-tumor necrosis factor efficacy tolerability, adverse events, and drug discontinuation were recorded. The percentage of patients who achieved the Psoriatic Arthritis Response Criteria (PSARC), the improvement of PAST, the improvement according to the American College of Rheumatology (ACR) criteria, and the disease activity for 28 joint indices score (DAS-28) were recorded.
Results: After 5 years, PSARC was 60%, PAST 70 was 66.7%, PAST 90 was 63.3%, while ACR 50 was 56.